Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Standard Lithium Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Standard Lithium Ltd trades at $2.46 (market cap $602.91M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 66.2× Standard Lithium Ltd's market cap. Which is the better fit depends on your goals.
| ALNY | SLI | |
|---|---|---|
Market Cap | $39.89B | $602.91M |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $5.65 |
52-Week Low | $278.09 | $2.29 |
Enterprise Value | $38.15B | $462.10M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Standard Lithium (SLI) trades at $2.46, down 3.15% today, showing bearish technical momentum despite unanimous analyst buy ratings. The company reported negative earnings with Q1 2026 beating expectations but Q4 2025 missing. Strong financing activities of $163.58M in 2025 support development of the South West Arkansas lithium project, with major operational milestones achieved at the demonstration plant.
The investment case hinges on successful project execution and lithium market dynamics. Near-term risks include negative cash flow from operations and high capital expenditures, but the $225M DOE grant and strategic partnerships provide funding stability. Analyst consensus remains strongly bullish with 100% buy ratings, viewing current weakness as a buying opportunity for long-term lithium exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
